I haven’t analysed in detail. But here are my thoughts:

Credo Brands reported doubling of sales in 2023 as compared to 2021. What caused this sudden spike in sales and OPM to zoom to 30+ from 18-20 percent?

If I am being totally conservative and assign pre 2021 OPM of 20 percent on sales of 500 crore, PBT will be around 50-60 crores and PAT to be 40-45 crores based on 25 percent tax. Total number of outstanding shares are 6.5 crores. That gives us an EPS of 6-7 and P/E of about 30 on CMP. Things to ponder:

1. Why did the sales double in just two years of time? Has management given us a concrete reason?
2. Will they be able to maintain this rate? I think market is not sure about this and that’s why the price is down 40 percent from listing.
3. Based on CMP of 200-210, it appears it is priced to perfection.

Disc – No holding.

Thanks,
Varun

Does anyone have any clue as to why NH is still continuing to fall with no bottom in sight? For all the other hospital sector players like Apollo, Fortis, Max, etc., I can see the intensity of the fall somewhat tapering down and indications of a bottom forming, while NH continues to fall steeply every single day.

Given that their P/E multiple is lower than other competitors and that their strategy is primarily centered around patient volumes and not pricing, I would think that any regulatory setback should affect them to a lesser degree. Am I getting something wrong here? Is NH overvalued with respect to competition?

After having two consecutive 40% of draw down, it was expected IIFL to bounce back. This is the market for you. The day RBI lifts ban, hopefully sooner, it may reach to the level of 600+. Now they have a support of $200 M support for the liquidity and gold hitting the all time high!

326 shares or 326K shares? On the same topic, saw this in ET and thought of sharing.

Tata investment has 6% stake in Tata Chemicals.